Wegovy and Ozempic share the same molecule — semaglutide — yet they are distinct FDA-approved products with different indications, dose ceilings, and pricing structures. Understanding those differences helps patients and prescribers choose the right product for the right reason.
At a Glance
| Criteria | Wegovy | Ozempic |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA Approval | Chronic weight management (adults & adolescents ≥12) | Type 2 diabetes management; cardiovascular risk reduction |
| Approved Max Dose | 2.4 mg/week | 2.0 mg/week |
| List Price (monthly est.) | ~$1,349–$1,650 | ~$935–$1,030 |
| Dosing Schedule | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Availability | Intermittently limited; separate pen device | Generally more available; separate pen device |
| Labeled For | Obesity / overweight with weight-related comorbidity | Type 2 diabetes; also reduces major cardiovascular events |
Active Ingredient
Both Wegovy and Ozempic contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Semaglutide works by mimicking the GLP-1 hormone, which stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite signals in the brain. Because the molecule is identical, the mechanism of action — and the side effect profile — is essentially the same across both products.
The formulation of semaglutide in each pen is also chemically identical; what differs is the concentration per pre-filled dose and the titration schedule designed to reach each product's target maintenance dose. Patients who switch between the two products are, pharmacologically speaking, still receiving the same drug.
FDA Approval & Intended Use
Wegovy received FDA approval in June 2021 specifically for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. In 2023, its approval was extended to adolescents aged 12 and older meeting similar BMI criteria. Notably, in March 2024, Wegovy also received an FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight — making it the first weight-loss drug with that label.
Ozempic was approved in December 2017 for glycemic control in adults with type 2 diabetes, and later for reducing the risk of major adverse cardiovascular events in those patients. It has never received FDA approval for weight loss as a primary indication. Prescribing Ozempic for weight management in patients without type 2 diabetes is considered off-label use — a legal and common practice, but one with insurance coverage implications.
Dosing & Titration
Both drugs follow a gradual titration schedule to minimize gastrointestinal side effects. Wegovy starts at 0.25 mg/week for four weeks, then steps up through 0.5 mg, 1.0 mg, and 1.7 mg over successive four-week intervals before reaching the maintenance dose of 2.4 mg/week — a 16-week escalation. Ozempic starts at 0.25 mg/week for four weeks, then moves to 0.5 mg, with optional increases to 1.0 mg and a maximum of 2.0 mg depending on glycemic response and tolerability.
The higher ceiling dose in Wegovy (2.4 mg vs. 2.0 mg) is clinically significant: the STEP clinical trials that supported Wegovy's approval demonstrated that the 2.4 mg dose produced mean weight loss of approximately 15% of body weight over 68 weeks, a magnitude not studied or labeled for Ozempic's approved doses in its own trials.
Cost & Insurance Coverage
List prices for both medications are substantial, but Wegovy typically carries a higher sticker price — roughly $1,349–$1,650 per month depending on dose and pharmacy — compared to Ozempic's approximately $935–$1,030 per month. Both Novo Nordisk savings cards can reduce out-of-pocket costs for eligible commercially insured patients, sometimes to as low as $25/month. However, program eligibility, income limits, and plan restrictions vary widely.
Insurance coverage is a major practical differentiator. Medicare Part D is prohibited by law from covering weight-loss drugs, meaning Wegovy is generally not covered for Medicare beneficiaries unless prescribed for its cardiovascular indication. Ozempic, as a diabetes drug, has broader Medicare and Medicaid coverage. Private insurance plans differ significantly: many cover Ozempic for diabetes but exclude or require prior authorization for Wegovy. Patients should verify coverage with their specific plan before starting either medication.
Availability & Supply
Both medications have experienced supply shortages since 2022 due to surging demand, but Wegovy has historically faced more pronounced and prolonged shortages, particularly at lower starter doses. Novo Nordisk has reported investments in manufacturing capacity, and availability has improved in some markets, though it remains inconsistent across pharmacies and regions. Ozempic, while also affected by shortages, has generally been more consistently available at retail pharmacies.
The FDA's drug shortage database and individual pharmacy stock-checking tools are the most reliable way to assess real-time availability. Some patients have been switched between the two products by prescribers during periods of shortage, a practice that requires careful attention to dose equivalency and coverage implications.
Side Effects & Safety Profile
Because both products contain semaglutide, their side effect profiles are nearly identical. The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, particularly during dose escalation. These effects are generally transient and lessen as the body adjusts. Serious but less common risks include pancreatitis, gallbladder disease, tachycardia, and a theoretical risk of thyroid C-cell tumors observed in rodent studies — a black box warning present on both labels.
One practical difference: Wegovy's higher 2.4 mg maintenance dose may be associated with a modestly higher rate of GI side effects compared to the 1.0 mg dose commonly used in Ozempic-treated diabetes patients, though individual tolerability varies considerably. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated for both medications.
Key Takeaway
Wegovy and Ozempic are the same molecule at different dose ceilings, approved by the FDA for different primary indications. Wegovy is purpose-built and labeled for weight management at a higher maximum dose, while Ozempic is approved for type 2 diabetes and cardiovascular risk reduction. The choice between them is largely determined by a patient's diagnosis, insurance coverage, prescriber judgment, and local availability — not by a meaningful pharmacological difference between the two products.